AlphaValue lifts target to EUR 253 for Sartorius Stedim stock

Published on 10/15/2026 at 10:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Finimize says AlphaValue expects wider margins from 2027. Sartorius Stedim stock costs EUR 217.60 on October 15, 2026, 14.00 percent below target.

Analyst target and reporting date

AlphaValue/Baader Europe set a EUR 253.00 target while lowering its 2026 earnings forecast.
Sartorius Stedim reported EUR 1.527 billion in first-half revenue on July 22, 2026.
Sartorius Stedim stock trades at EUR 217.60 at 10:02 a.m. CEST at Lang & Schwarz on October 15, 2026.
The company schedules its nine-month 2026 results for October 22, 2026.

Redaktionsfoto eines Euronext-Pariser Handelsfloors mit Kursdiagrammen im Healthcare-Sektor — Sartorius Stedim Biotech Euronext Paris Handelsfloor mit Tradern und großen Kursdiagrammen im Healthcare-Sektor, ISIN FR0013154002, Illustration mit AI erstellt.

Sartorius Stedim Biotech (ISIN FR0013154002) is trading at EUR 217.60 at Lang & Schwarz on October 15, 2026, while AlphaValue/Baader Europe has set a EUR 253.00 price target. Finimize reports that the analyst firm expects faster growth and wider margins from 2027, even after reducing its earnings forecasts.

Target rises as forecasts fall

AlphaValue/Baader Europe cut its 2026 and 2027 earnings-per-share forecasts by 9.20 percent and 7.96 percent to EUR 4.69 and EUR 5.72. The note attributed the reductions to higher depreciation and amortization assumptions following the first-half 2026 run rate. Its EUR 253.00 target instead reflects higher discounted cash flow and net asset value estimates, together with expected benefits from consumables and deleveraging, according to Finimize.

What supports the margin case?

The latest reported figures provide the operating baseline. Sartorius Stedim posted EUR 1.527 billion of revenue, EUR 463.70 million of EBITDA, a 31.40 percent EBITDA margin and EUR 181.10 million of net income for the first half of 2026, according to Ideal Investisseur. The company page states that recurring consumables are central to its model and that its 2026 outlook calls for sales growth of 6 to 10 percent in constant currencies and an underlying EBITDA margin slightly above 31 percent, according to Sartorius Stedim Biotech.

Results date is October 22

The next scheduled corporate milestone is the nine-month 2026 results presentation on October 22, 2026, with a conference call at 1:00 p.m. CEST, as stated on the company's investor-relations page. That date will test whether the recovery in bioprocess demand is beginning to translate into the margin expansion used in the analyst case.

Stock price and investor context

The EUR 253.00 target is 14.00 percent above the Lang & Schwarz price of EUR 217.60. The contrast between lower near-term earnings estimates and a higher valuation target leaves cash generation, consumables growth and operating leverage as the key points for the next update.

Sartorius Stedim was trading at EUR 217.60 at Lang & Schwarz on October 15, 2026, at 10:02 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Sartorius Stedim stock.